Prophylaxis of Serious Cytomegalovirus Infection in Renal Transplant Candidates Using Live Human Cytomegalovirus Vaccine

Kl, Brayman; Dc, Dafoe; Wr, Smythe; Cf, Barker; Lj, Perloff; Naji, Ali; Ij, Fox; Ra, Grossman; Dk, Jorkasky; Se, Starr

doi:10.1001/archsurg.1988.01400360072012

Cited by 45 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In theory, one of the simplest interventions for the prevention of CMV disease after transplantation would be immunization of seronegative recipients with a vaccine given once in anticipation of future viral challenge. A live attenuated CMV vaccine, which uses the Towne strain of virus, is both safe and immunogenic; however, there is no significant decrease in the incidence of CMV disease in renal transplant recipients receiving this vaccine, although there is a decrease in the severity of CMV disease in the donor seropositive/recipient-seronegative (Dϩ/RϪ) subgroup (32,33,74,220,424,532,534,535). New interest in developing a vaccine subunit product has emerged over the last few years (533).…”

Section: Cytomegalovirusmentioning

confidence: 99%

Infections in solid-organ transplant recipients

1997

View full text Add to dashboard Cite

Solid-organ transplantation is a therapeutic option for many human diseases. Infections are a major complication of solid-organ transplantation. All candidates should undergo a thorough infectious-disease screening prior to transplantation. There are three time frames, influenced by surgical factors, the level of immunosuppression, and environmental exposures, during which infections of specific types most frequently occur posttransplantation. Most infections during the first month are related to surgical complications. Opportunistic infections typically occur from the second to the sixth month. During the late posttransplant period (beyond 6 months), transplantation recipients suffer from the same infections seen in the general community. Opportunistic bacterial infections seen in transplant recipients include those caused by Legionella spp., Nocardia spp., Salmonella spp., and Listeria monocytogenes. Cytomegalovirus is the most common cause of viral infections. Herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and others are also significant pathogens. Fungal infections, caused by both yeasts and mycelial fungi, are associated with the highest mortality rates. Mycobacterial, pneumocystis, and parasitic diseases may also occur.

show abstract

Section: Cytomegalovirusmentioning

confidence: 99%

Infections in solid-organ transplant recipients

1997

View full text Add to dashboard Cite

show abstract

“…Although infection was not prevented, a subgroup of vaccinated patients did exhibit less severe disease manifestations. 37,43 A nonreplicating canarypox vector encoding HCMV gB has been investigated in Phase I studies alone and in combination with recombinant gB, 44,45 and a canarypox vaccine encoding pp65 has also been studied. 46 The latter induced CTL, lymphoproliferation, and antibody responses in all seronegative recipients in these Phase I trials.…”

mentioning

confidence: 99%

A DNA-Based Vaccine for the Prevention of Human Cytomegalovirus-Associated Diseases

Selinsky

Luke²,

Wloch³

et al. 2005

Human Vaccines

View full text Add to dashboard Cite

“…More recently, the Plotkin group (Brayman et al, 1988) provided data that seemed to support the type of protection suggested by Balfour et al (1985). As previously reported, the vaccine did not decrease infection rates or symptomatic CMV infection.…”

Section: Towne 125 Vaccinementioning

confidence: 66%

Cytomegalovirus

1991

View full text Add to dashboard Cite

All rights reserved 90-14345 CIP No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher Preface to the First EditionAlthough there are a number of excellent current reviews on one or another aspect of cytomegalovirus, the last comprehensive treatment of this subject was that of Krech et al. (197la). In view of the amazing advances in the virological, epidemiologic, and clinical knowledge of cytomegaloviruses, an up-to-date book is needed. Such a work should cover many areas of expertise and a voluminous technical literature. Each area might have been reviewed and analyzed by workers more expert than myself. However, I have embarked on the entire venture alone in order to attain unity and continuity in this book, characteristics that are not easily achieved in the more popular multiauthored works. I have tried to review the Iiterature and provide a critical summary for each area discussed. To do this, I provide as much of the primary data of the relevant works as needed and not just the qualitative conclusions. Inevitably, the flow of the narrative may be interrupted by dry facts and figures. However, such information is essential to make this a meaningful reference work. But for those not interested in such details, I have provided at what I hope are crucial points critiques and summaries.This book is not an exhaustive review of all the literature. This is probably no Ionger possible or even desirable. By selection, however, one runs the risk of having missed or ignored important papers. I am keenly aware of this, and I wish to apologize for such oversight, if that is possible.I visualize this work as being useful for physicians, scientists, and students interested in the biology of and infection by human cytomegalovirus. I feel that to understand these, the basic virology of this virus and related herpesviruses must be included. Topics that have not advanced a great deal and that are adequately described in available works, such as the anatomic pathology, have not been reviewed in detail. The emphasis has been placed on newer insights in the virology, immunology, serology, epidemiology, and especially clinical aspects of human cytomegalovirus. I wish tobring out the interactions of knowledge in these areas. Part II is a much shorter treatment of the nonhuman cytomegaloviruses, reviewed primarily from the point of view of their contribution to the understanding of the human virus. V vi Preface to the First Edition Finally, I wish to thank Drs. Charles R. Rinaldo, Jr., John A. Armstrong, and Donald N. Medearis for their critical review of the manuscript. Their suggestions were invaluable. Dr. John N. Dowling's thorough review of CMV infection in patients with malignancies was the basis of Section 13.4. I also acknowledge the indispensable and patient secretarial assistance of Ms.The remarkable medical events and advances in knowle...

show abstract

Prophylaxis of Serious Cytomegalovirus Infection in Renal Transplant Candidates Using Live Human Cytomegalovirus Vaccine

Cited by 45 publications

References 20 publications

Infections in solid-organ transplant recipients

Infections in solid-organ transplant recipients

A DNA-Based Vaccine for the Prevention of Human Cytomegalovirus-Associated Diseases

Cytomegalovirus

Contact Info

Product

Resources

About